Molecule
operates the leading DeSci infrastructure for tokenizing biotech intellectual property as IP-NFTs; its Molecule Protocol V2, launched in 2025, integrates these IP-backed tokens with traditional corporate equity as a new "real-world asset" class,…
- Country
- Switzerland
ip-nft
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Crowdfunding & retail investment in biotech | finance-investment | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.